Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955006 · ClinicalTrials.gov registry record · Phase 1
Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00955006 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 17 participants.
The verdict
NCT00955006, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
Interventions
- BIOLOGICAL VRC-HIVDNA-016-00-VP
- BIOLOGICAL VRCHIVADV014-00-VP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955006
The ClinicalTrials.gov registry entry for NCT00955006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VRC-HIVDNA-016-00-VP is the first listed.
NCT00955006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955006 about?
NCT00955006 is a clinical study titled "Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals". The purpose of the study is to determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
What is the current status of trial NCT00955006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2011-05. Estimated completion is 2017-11-22.
What interventions are being tested in trial NCT00955006?
The interventions under investigation include: VRC-HIVDNA-016-00-VP (BIOLOGICAL), VRCHIVADV014-00-VP (BIOLOGICAL).
Who is sponsoring clinical trial NCT00955006?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.